Comparative studies of dipeptidyl peptidase 4 inhibitor vs sulphonylurea among Muslim Type 2 diabetes patients who fast in the month of Ramadan: A systematic review and meta-analysis. Issue 3 (June 2016)

• Record Type: Journal Article
• Authors: Loh, Huai Heng; Yee, Anne; Loh, Huai Seng; Sukor, Norlela; Kamaruddin, Nor Azmi
• Is Part Of: Primary care diabetes. Volume 10:Issue 3(2016)
• Page Start: 210
• Page End: 219
• Publication Date: 2016-06
• Subjects: Dipeptidyl peptidase-4 inhibitor -- Ramadan fasting -- Sulphonylurea -- Type 2 diabetes mellitus; Diabetes -- Periodicals; 616.462
• DOI: 10.1016/j.pcd.2015.09.001
• Languages: English
• ISSNs: 1751-9918

Abstract

Highlights: DPP4 inhibitor has lower risk of hypoglycemia when used during fasting months. Vildagliptin has efficacy in glucose control which is comparable to sulphonylurea. DPP4 inhibitor is a safer alternative for Muslim patients with Type 2 diabetes. Abstract: Aim: To systematically review the literature to compare the use of DPP4 inhibitors vs sulphonylurea in type 2 diabetic Muslim patients who fast in Ramadan, with regards to its safety, tolerability, glycemic control, and body weight changes. Methods: All English-language medical literature published from inception till October 2014 which met the inclusion criteria were reviewed and analyzed. Results: A total of nine papers were included, reviewed and analyzed. The total sample size was 4276 patients. All studies used either of the two DPP4 inhibitors – Vildagliptin or Sitagliptin, vs sulphonylurea or meglitinides. Patients receiving DPP4 inhibitors were less likely to develop symptomatic hypoglycemia (risk ratio 0.46; 95% CI, 0.30–0.70), confirmed hypoglycemia (risk ratio 0.36; 95% CI, 0.21–0.64) and severe hypoglycemia (risk ratio 0.22; 95% CI, 0.10–0.53) compared with patients on sulphonylureas. There was no statistically significant difference in HbA1C changes comparing Vildagliptin and sulphonylurea. Conclusion: DPP4 inhibitor is a safer alternative to sulphonylurea in Muslim patients with type 2 diabetes mellitus who fast during the month of Ramadan as it is associated with lower risk of symptomatic, confirmed and severe hypoglycemia, with efficacy comparable to sulphonylurea.